Multiple Infliximab Biosimilar Switches Appear Safe, Effective for Patients With IBDApril 20th 2023
A retrospective study in Scotland found that multiple successive changes from originator infliximab to biosimilars seem to be safe and effective in patients with inflammatory bowel disease (IBD), irrespective of the number of switches.
Christine Baeder Discusses the Future of the Biosimilar Industry, InsulinsApril 9th 2023
Upon coming into her position as the new chair of the Association for Accessible Medicines (AAM), Christine Baeder discussed what she believes the future holds for biosimilars, good and bad, and the questions that still surround the insulin price cap.
Christine Baeder Discusses Generic Awareness and Challenges that Lie in Biosimilar in Generic SpacesMarch 28th 2023
Upon coming into her position as the new chair of the Association for Accessible Medicines (AAM) as well as chief operating officer for US generics and biosimilars at Teva Pharmaceuticals USA, Christine Baeder discusses her primary goals in this position, and the challenges that accompany them.
Favorable Equivalency Studies of Candidate Biosimilar AVT04 and Reference UstekinumabMarch 27th 2023
Posters presented by Alvotech at 2023 American Academy of Dermatology (AAD) annual meeting showcased proven bioequivalence and therapeutic equivalence candidate biosimilar AVT04 and reference ustekinumab (Stelara).
Comparable Safety, Efficacy Between First Proposed Natalizumab Biosimilar, Reference for MSMarch 3rd 2023
Phase 3 study findings support a proposed natalizumab biosimilar (PB006) as the first biosimilar alternative to reference natalizumab (Tysabri) for treatment of relapsing-remitting multiple sclerosis (MS).
ACR Supports Affordable Treatments, Use of Biosimilars Following Rigorous Approval ProcessFebruary 27th 2023
The American College of Rheumatology (ACR) steadfastly supports the availability of safe and effective treatments for patients at the lowest cost possible, and underscores the necessity of scientific rigor for biosimilar use and approval.
Patients With RA, IBD Trust Specialists’ Biologic and Biosimilar RecommendationsFebruary 24th 2023
Patients with rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) have similar positive attitudes towards biologics and both trust their specialists’ recommendations, according to a recent survey conducted in Australia.
Phase 4 Study Finds Comparable Safety, Efficacy Between Etanercept Biosimilar, Enbrel for Autoimmune DiseasesFebruary 10th 2023
The first phase 4 postmarketing surveillance study for SB4 in South Korea as the first approved biosimilar of etanercept demonstrated comparable effectiveness and safety to previous SB4 evidence.